ALLAKOS - Key Persons

Job Titles:

• Member of the Management Team
• President

Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor relation functions through the company's initial public offering and sale to AstraZeneca. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and Allakos. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics. Dr. Tomasi holds a Bachelor of Science in Chemistry from the University of California, Berkeley, an MBA from MIT and a PhD in Chemistry from the University of California, Irvine.

Job Titles:

• Member of the Audit Committee
• Compensation Committee / Nominating and Corporate Governance Committee
• Member of Our Board of Directors

Dr. Ladd has served as a member of our Board of Directors since July 2022 and has spent three decades practicing orthopaedic surgery at Stanford University. She currently serves as the Elsbach-Richards Professor of Surgery, Professor of Orthopaedic Surgery as well as Professor of Medicine (Immunology & Rheumatology), by courtesy, at the Stanford Universal Medical Center. Dr. Ladd is also a member of the board of directors for Intuitive Surgical, Inc. and the Perry Initiative. Previously, she served as the chair of the American Academy of Orthopaedic Surgeons (AAOS) Board of Specialties Society and is a past member of the AAOS board of directors. Dr. Ladd received her M.D. from SUNY Upstate Medical University, completed her Orthopaedic Residency at the University of Rochester and completed the Harvard Combined Hand Surgery Fellowship. Prior to joining the Stanford University faculty, Dr. Ladd was a fellow at L'Institut de la Main in Paris, France. She earned her A.B. in History from Dartmouth College.

Job Titles:

• CHIEF FINANCIAL OFFICER
• Member of the Management Team

Mr. Radford has over 25 years of public company finance and leadership experience at companies in multiple industries and various stages of growth including providing financial operations leadership to commercial-stage companies. Prior to Allakos, as Senior Vice President of Finance at Aimmune Therapeutics, Mr. Radford was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow, a medical technology company with commercial operations in the United States, Canada, Europe and Japan. Prior to joining HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, with responsibility for financial planning and analysis, investor relations and enterprise analytics. Prior to Intuitive Surgical, Mr. Radford held various positions at eBay, including Vice President of Finance for Marketplaces Europe, as well as Vice President, Corporate Controller, and Chief Accounting Officer. Mr. Radford began his career in the audit practice of PricewaterhouseCoopers. Mr. Radford has a BBA from Ohio University.

Job Titles:

• Co - Founder
• Physician

Dr. Bochner is a co-founder of Allakos and has been a member of its Scientific Advisory Board since 2012. Dr. Bochner is a physician-scientist and co-discoverer of Siglec-8. His ongoing NIH-funded research work focuses on the glycobiology and function of Siglec-8 and related inhibitory receptors on cells of the immune system. He is the author of more than 295 peer-reviewed publications, reviews, and book chapters, with an interest in the mechanisms of allergic cell recruitment, activation and survival in human allergic inflammatory responses. Dr. Bochner is a Fellow of the American Academy of Allergy, Asthma, and Immunology, and a member of the Omega Alpha Omega Medical Honors Society, the American Society for Clinical Investigation, and the Association of American Physicians. He is the Immediate Past President of the International Eosinophil Society and the current President of the Collegium Internationale Allergologicum. He previously served on the Board of Directors of the American Board of Allergy and Immunology and the Board of Directors for the American Academy of Allergy, Asthma, and Immunology. He is co-Editor-in-Chief for the Allergy and Immunology Section of the online resource UpToDate and was a co-editor of the Middleton's Allergy: Principles and Practice textbook. Prior to his current position, he was Professor of Medicine in the Division of Allergy and Clinical Immunology and a Cosner Scholar in Translational Research at the Johns Hopkins University School of Medicine and was Division Director from 2003-2013. Dr. Bochner received a Bachelor of Arts degree with honors in Natural Sciences from the Johns Hopkins University in Baltimore, Maryland and attended medical school at the University of Illinois College of Medicine in Chicago, where he again graduated with honors. He is board-certified in both Internal Medicine and Allergy and Immunology.

Job Titles:

• Chief Medical Officer
• Member of the Management Team

Dr. Lee has over 20 years of clinical research & development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused on the development of small molecules and biologic therapies for immune mediated conditions. Prior to Allakos, Dr. Lee served as the Chief Medical Officer at Connect Biopharma, a clinical-stage company focused on development of innovative therapies for chronic inflammatory diseases based on T cell-driven research. Dr. Lee also previously served as Vice President, Head of Clinical Science, and Chief Medical Officer at Theravance Biopharma, Inc, Lead Group Medical Director within the Genentech Research & Early Development (gRED) group, as well held roles of increasing responsibility within the Immunology Therapeutic Area at Eli Lilly & Co., and the Immunoscience Group at Abbott (now Abbvie). During his time in industry, Dr. Lee has successfully led the submission of global regulatory filings and participated in product commercialization across multiple autoimmune and immunology disease indications. Prior to entering the biopharmaceutical industry, Dr. Lee was on the academic faculty at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received his BS in Biology and an MD from the University of North Carolina at Chapel Hill, and an MPH from Northwestern University.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Chairman ) Alta Partners, Managing Director
• Compensation Committee / Nominating and Corporate Governance Committee
• Managing Partner of Alta Partners
• Member of the President 's Council

Dan Janney is the Managing Partner of Alta Partners. Mr. Janney joined Alta Partners at its founding in 1996. He has nearly 25 years of successful early-stage investing experience in life sciences. Mr. Janney's focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, he was a senior investment banker at Montgomery Securities. Mr. Janney is currently on the board of directors of several public and private companies, including Be Biopharma, Curasen Therapeutics, ImmuneID, Krystal Biotech, Lassen Therapeutics, Novome Biotechnologies, and Prolacta Bioscience. In addition, he led Alta's investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (acquired by Cephalon), CoTherix (acquired by Actelion), Definity Health (acquired by United Health), Dynavax, Endonetics (acquired by Medtronic), Esperion Therapeutics, Ilex Oncology (acquired by Millennium Pharmaceuticals), InterMune (acquired by Roche), LJL Biosystems (acquired by Molecular Devices), Mako Surgical (acquired by Stryker) and Triangle Pharmaceuticals (acquired by Gilead). Mr. Janney is a member of The President's Council of the J. David Gladstone Institutes and the chair of the Board of Directors of the California Academy of Sciences. He also serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts from Georgetown University and a MBA from the Anderson School at the University of California, Los Angeles.

Job Titles:

• Venture Partner With Samsara BioCapital

Dr. Thomas is a Venture Partner with Samsara BioCapital and currently serves on the board of directors of Chinook Therapeutics, Inc. and Ventus Therapeutics, Inc. Among other experiences, Dr. Thomas was the Executive Vice President, Head of Research and Development and Chief Medical Officer at Equillium, Inc. as well as the Chief Medical Officer at Principia Biopharma, Inc. and she received her M.D. from Cornell University.

Job Titles:

• Chief Technical Officer
• Member of the Management Team

Dr. Cromwell has more than 30 years' experience in the biotechnology industry. Prior to joining Allakos, Dr. Cromwell was Vice President for Quality, Drug Substance at Genentech/Roche. She began her career at Genentech in the Pharmaceutical Development group where she developed formulations for several molecules in various stages of development. She has held leadership positions in Protein Analytical Chemistry, Pharmaceutical Development, and Global Biologics Manufacturing Sciences and Technologies & Global Packaging Development prior to her role in Quality. Dr. Cromwell was directly involved in the licensure of numerous Genentech/Roche products, including Avastin® and Perjeta®. She served as a member of the Genentech Foundation Board, a non-profit organization that provided funding to improve the success of students from underrepresented groups in post-secondary STEM education. Dr. Cromwell received a BS in Chemistry from West Virginia University, an MS in Biophysical Chemistry from the University of California-Berkeley, and a PhD in Pharmaceutical Sciences from the University of Colorado-Denver.

Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc. and he received his M.D. from the University of Adelaide.

Job Titles:

• Member of the Audit Committee
• Audit Committee / Compensation Committee
• NEW ENTERPRISE ASSOCIATES, PARTNER
• Partner at New Enterprise Associates

Paul Walker has more than 20 years of life sciences investing experience. Mr. Walker has been a Partner at New Enterprise Associates, an investment firm focused on venture capital and growth equity investments, since 2008. He focuses on later-stage biotechnology and life sciences investments. In 2001, Mr. Walker joined MPM Capital and was a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Mr. Walker received a Bachelor of Science in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst designation.

Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well as Sanofi and he received his M.D. from the University of Chicago.

Job Titles:

• Chief Executive Officer
• Member of the Board of Directors
• Member of the Management Team

Dr. Alexander has been involved in the formation and leadership of numerous biotechnology companies. Dr. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Dr. Alexander was a Principal in MPM Capital's BioEquities Fund. Robert joined MPM from Genentech, where he worked in the Business Development group. Dr. Alexander holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor of Science in Zoology from Miami University of Ohio.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Audit Committee
• GOOGLE LLC, VICE PRESIDENT, CONTROLLER
• Member of Our Board of Directors

Robert Andreatta has served as a member of our Board of Directors since June 2018, and has more than three decades of corporate finance and accounting experience. Mr. Andreatta has served as Vice President, Controller at Google since March 2016. Prior to Google, Mr. Andreatta was the Vice President, Controller and Chief Accounting Officer at Genentech from 2008 to 2016. Andreatta joined Genentech in 2003 as Director, Collaborations Finance, and has held positions of increasing responsibility including Director, Corporate Accounting and Reporting, Senior Director, Corporate Finance and Assistant Controller, Controller and Chief Accounting Officer. Prior to joining Genentech, Mr. Andreatta held various officer positions at HopeLink Corporation, a healthcare information technology company, and was a member of the Board of Directors of HopeLink. Prior to joining HopeLink, Mr. Andreatta was an audit partner with KPMG. Mr. Andreatta earned a Bachelor of Science degree in accounting from Santa Clara University.

Job Titles:

• Co - Founder
• Expert
• the ROY and ELAINE PATTERSON PROFESSOR EMERITUS of MEDICINE, CHIEF of ALLERGY and IMMUNOLOGY, NORTHWESTERN UNIVERSITY

Dr. Schleimer is a co-founder of Allakos and has been a member of its Scientific Advisory Board since 2012. Dr. Schleimer is an expert in the molecular mechanisms of allergic disease, focusing on inflammation, innate and adaptive immunity and is a co-discoverer of Siglec-8. Dr. Schleimer has published over 400 papers and was recognized as one of the most highly cited researchers worldwide by The Institute for Scientific Information (ISI). Dr. Schleimer has served on numerous boards and review committees for the NIH and on dozens of scientific and medical advisory boards for pharma, biotech and startup companies. He has also been on the editorial board of numerous medical journals relevant to Allergy and Immunology. Prior to his current position at Northwestern, Dr. Schleimer was Professor of Medicine at the Johns Hopkins University School of Medicine in the Division of Allergy and Clinical Immunology. Dr. Schleimer's laboratory has had continuous funding from the NIH for over 35 years. Dr. Schleimer majored in Biology at The University of California at San Diego and received a PhD in Pharmacology and Toxicology at University of California at Davis.

Job Titles:

• Member of the Audit Committee
• Audit Committee
• Biopharma Executive

Steven James has over 35 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James was most recently president and Chief Executive Officer and director of Pionyr Immunotherapeutics until it was acquired by Ikena Oncology. Previously, he was president and Chief Executive Officer of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and Chief Executive Officer of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Mr. James is currently a director of Ventus Therapeutics and Lyterian Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt), Cascadian Therapeutics (acquired by Seattle Genetics), Antiva Biosciences, and Soteria Therapeutics.